English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The current strategy for treating the Covid-19 coronavirus disease involves the repurposing of existing drugs or the use of convalescent plasma therapy, as no specific therapeutic intervention has yet received regulatory approval. However, severe adverse effects have been reported for some of these repurposed drugs. Recently, several in silico studies have identified compounds that are potential inhibitors of the main protease (3-chymotrypsin-like cysteine protease) and the nucleocapsid protein of SARS-CoV-2. An essential step of drug development is the careful evaluation of toxicity, which has a range of associated financial, temporal and ethical limitations. In this study, a number of in silico tools were used to predict the toxicity of 19 experimental compounds. A range of web-based servers and applications were used to predict hepatotoxicity, mutagenicity, acute oral toxicity, carcinogenicity, cardiotoxicity, and other potential adverse effects. The compounds were assessed based on the consensus of results, and were labelled as positive or negative for a particular toxicity endpoint. The compounds were then categorised into three classes, according to their predicted toxicity. Ten compounds (52.6%) were predicted to be non-mutagenic and non-hERG inhibitors, and exhibited zero or low level hepatotoxicity and carcinogenicity. Furthermore, from the consensus of results, all 19 compounds were predicted to be non-mutagenic and negative for acute oral toxicity. Overall, most of the compounds displayed encouraging toxicity profiles. These results can assist further lead optimisation studies and drug development efforts to combat Covid-19.

The Use of In Silico Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2